Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 181

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells

Open access
Kovtun, Yelena, Jones, Gregory E., Adams, Sharlene, Harvey, Lauren, Audette, Charlene A., Wilhelm, Alan, Bai, Chen, Rui, Lingyun, Laleau, Rassol, Liu, Fenghua, Ab, Olga, Setiady, Yulius, Yoder, Nicholas C., Goldmacher, Victor S., Chari, Ravi V. J., Pinkas, Jan, Chittenden, Thomas · 2018 · Blood Advances

Abstract

Key Points: IMGN632 is a conjugate of a novel CD123-targeting antibody with a highly potent DNA alkylating payload. IMGN632 is active in preclinical models of AML with poor prognosis at concentrations far below levels that impact normal bone marrow cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2018017517

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 181

Metadata

Authors
Kovtun, Y., Jones, G. E., Adams, S., Harvey, L., Audette, C. A., Wilhelm, A., Bai, C., Rui, L., Laleau, R., Liu, F., Ab, O., Setiady, Y., Yoder, N. C., Goldmacher, V. S., Chari, R. V. J., Pinkas, J., & Chittenden, T.
Venue
Blood Advances
Published
2018-04-16
Volume
2
Issue
8
Pages
848-858
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W2800912743
Cited by
181
References
3
FWCI
12.16
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. https://app.cochat.ai/papers/10.1182/bloodadvances.2018017517
The paper
Kovtun, Y., Jones, G. E., Adams, S., Harvey, L., Audette, C. A., Wilhelm, A., Bai, C., Rui, L., Laleau, R., Liu, F., Ab, O., Setiady, Y., Yoder, N. C., Goldmacher, V. S., Chari, R. V. J., Pinkas, J., & Chittenden, T. (2018). A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Advances. https://doi.org/10.1182/bloodadvances.2018017517

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.